MIRA INFORM REPORT

 

 

Report Date :

20.02.2014

 

IDENTIFICATION DETAILS

 

Name :

VERGO PHARMA RESEARCH LABORATORIES PRIVATE LIMITED

 

 

Registered Office :

Keni Building, Dr. Dada Vaidya Road, Panaji, Goa – 403 001, Maharashtra

 

 

Country :

India

 

 

Financials (as on) :

31.03.2013

 

 

Date of Incorporation :

10.08.2010

 

 

Com. Reg. No.:

11-006462

 

 

Capital Investment / Paid-up Capital :

Rs.25.100 Millions

 

 

CIN No.:

[Company Identification No.]

U73200GA2010PTC006462

 

 

Legal Form :

Private Limited Liability Company

 

 

Line of Business :

The Company is in the Business of carrying Pharmaceutical Research Work at Varna, Goa.

 

 

No. of Employees :

160 (Approximately)

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ca (12)

 

RATING

STATUS

PROPOSED CREDIT LINE

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

Limited with full security

 

Status :

Moderate

 

 

Payment Behaviour :

Slow and delayed

 

 

Litigation :

Clear

 

 

Comments :

Subject is an established company having moderate track record.

 

The company has incurred huge accumulated losses, which has eroded the networth of the company. Profitability of the company seems to be under pressure.

 

Business is active. Payment terms are slow and delayed.

 

The company can be considered for business dealings on safe and secured trade terms and conditions.

 

NOTES:

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – December 1, 2013

 

Country Name

Previous Rating

(30.09.2013)

Current Rating

(01.12.2013)

India

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

 

 

 

INDIAN ECONOMIC OVERVIEW

 

The worst is over for India’s economy with gross domestic product likely to expand 5 %to 5.5 % this year and more than 6 % in 2015, according to Moody’s Analytics. Concerns over the rupee and current account deficit are under control, said the agency. Ratings firm Crisil has forecast 6 % growth for 2014/15 up from the estimated 4.8 % for 2013/14.  Total economic growth, infrastructure bottlenecks and lack of transparency and consistency in foreign direct investment policies seem to have taken a toll on India’s attractiveness as an investment destination, says an Ernst & Young survey.  Projects with FDI component fell 16.4 % across the globe in 2012 from the previous year.  The drop in India was steeper at 21 %. State run carrier Air India is doling out free tickets to its 24000 employees, even as it expects to incur a loss of Rs 39000 mn this financial year and has a debt of Rs 350000 mn. 550000 number of jobs generated across India in 2013, a fall of 0.4 % as compared to with a year earlier. The National Capital Region has a one-fourth share in total jobs created, according to a study by industry lobby group Assochem, Banks, real estate, automobile and telecommunications sectors are showing a rise of job creation. $ 805 mn investments by venture capital firms in India during 2013, registering a drop of about 18 % over the previous year. The Information Technology and IT-Enabled Services Industry retained its status as the favourable venture capital investors in 2013. Pakistan has temporarily banned gold imports for the second time in six months, as it tries to stem smuggling into India. India’s import duty on gold is 10 % and curbs on purchases have dried up legal imports into what used to be the world’s biggest bullion buyers. The World Gold Council puts the amount smuggled into India at upto 200 tonnes in 2013. The Reserve Bank of India has proposed that unclaimed bank deposits estimated to be about Rs 35000 mn be used for education and awareness among depositors.  According to the plan, deposits that have not been claimed for at least 10 years will be transferred to the scheme.

 

RBI DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

 

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2012.

 

INFORMATION PARTED BY

 

Name :

Mr. Buland Akbar

Designation :

Accounts Head

Contact No.:

91-9765755813

Date :

19.02.2014

 

 

LOCATIONS

 

Registered / Corporate Office:

Keni Building, Dr. Dada Vaidya Road, Panaji, Goa – 403 001, Maharashtra, India

Tel. No.:

91-832-2224753 / 2225956 / 2224309

Mobile No.:

91-9765755813 (Mr. Buland Akbar)

Fax No.:

91-832-2221310

E-Mail :

info@vergopharma.com

Website :

www.vergopharma.com

 

 

Clinical Center :

Plot 24/1- D-1, Mologa de Orora Corlim, Tiswadi, Goa – 403 110, Maharashtra, India

Tel. No.:

91-832-6640400

Fax No.:

91-832-6640565

 

 

R and D Center :

Plot B-5, 1A Verna Industrial Estate Verna, Salcette, Goa – 403 722, Maharashtra, India

Tel. No.:

91-832-6624858

Fax No.:

91-832-6624859

 

 

Asia Office :

301/302 Opulence, 6th Road, Santacruz (East), Mumbai – 400 055, Maharashtra, India

Tel. No.:

91-22-61955955

 

 

North America Office :

605 Gordon Drive, Suite B, Exton, PA 19341 USA

Tel. No.:

+1(484) 514-1861 Ext 200

Fax No.:

+1(484) 514-1866

 

 

Europe Office :

Haidersberggasse 8, A-1140 Vienna Austria

Tel. No.:

+43(1) 796 37 65

Fax No.:

+43(1) 796 37 66

 

 

DIRECTORS

 

AS ON 30.09.2013

 

Name :

Mr. Prasad Vassudeva Keni

Designation :

Managing Director

Address :

Laxmi Prasad, D. B. Bandodkar Marg, Panaji, North Goa – 403 001, Maharashtra, India

Date of Birth/Age :

08.06.1969

Date of Appointment :

01.09.2013

DIN No.:

00841272

Other Directorship:

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Company/ LLP Status

Defaulting status

1

U14219GA1993PTC001360

V.G. QUENIM MINING PRIVATE LIMITED.

Managing director

01/10/2007

20/05/1993

Active

NO

2

U74950GA1985PTC000625

VILMAN PACKAGINGS PRIVATE LIMITED

Managing director

01/10/2007

01/04/2000

Active

NO

3

U73200GA2010PTC006462

VERGO PHARMA RESEARCH LABORATORIES PRIVATE LIMITED

Managing director

01/09/2013

10/08/2010

Active

NO

4

U73100MH2010PTC208075

VERGO PHARMA RESEARCH PRIVATE LIMITED

Managing director

01/09/2013

23/09/2010

Active

NO

 

 

Name :

Mr. Vini Prasad Keni

Designation :

Director

Address :

Laxmi Prasad, D. B. Bandodkar Marg, Panaji, North Goa – 403 001, Maharashtra, India

Date of Birth/Age :

03.03.1970

Date of Appointment :

10.08.2010

DIN No.:

00841316

Other Directorship:

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Company/ LLP Status

Defaulting status

1

U74950GA1985PTC000625

VILMAN PACKAGINGS PRIVATE LIMITED

Director

10/04/2008

01/10/2006

Active

NO

2

U14219GA1993PTC001360

V.G. QUENIM MINING PRIVATE LIMITED.

Whole-time director

10/04/2008

10/04/2008

Active

NO

3

U73200GA2010PTC006462

VERGO PHARMA RESEARCH LABORATORIES PRIVATE LIMITED

Director

10/08/2010

10/08/2010

Active

NO

4

U73100MH2010PTC208075

VERGO PHARMA RESEARCH PRIVATE LIMITED

Director

23/09/2010

23/09/2010

Active

NO

 

 

Name :

Mr. Gajanan Jaivant Surlakar

Designation :

Director

Address :

T3, Aparna Apartment Housing Society, Dr. A. Borkar Road, Panaji, North Goa – 403 001, Maharashtra, India

Date of Birth/Age :

25.07.1948

Date of Appointment :

10.08.2010

DIN No.:

01293055

Other Directorship:

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Company/ LLP Status

Defaulting status

1

U14103GA1992PTC001272

KUDNEM MINERAL PROCESSING COMPANY PRIVATE LIMITED

Whole-time director

30/09/2007

01/02/2007

Active

NO

2

U73200GA2010PTC006462

VERGO PHARMA RESEARCH LABORATORIES PRIVATE LIMITED

Director

10/08/2010

10/08/2010

Active

NO

3

U73100MH2010PTC208075

VERGO PHARMA RESEARCH PRIVATE LIMITED

Director

23/09/2010

23/09/2010

Active

NO

 

 

KEY EXECUTIVES

 

Name :

Mr. Buland Akbar

Designation :

Accounts Head

 

 

MAJOR SHAREHOLDERS

 

AS ON 30.09.2013

 

Names of Shareholders

 

No. of Shares

% of holding

Prasad Vassudeva Keni

150500

59.96

Vini Prasad Keni

100500

40.04

Total

251000

100.00

 

 

Equity Share Break up (Percentage of Total Equity)

 

AS ON 30.09.2013

 

Category

Percentage

Directors or relatives of Directors

100.00

 

 

Total

100.00

 

 

BUSINESS DETAILS

 

Line of Business :

The Company is in the Business of carrying Pharmaceutical Research Work at Varna, Goa.

 

 

Terms :

 

Selling :

Credit, Cheque

 

 

Purchasing :

Credit, Cheque

 

 

GENERAL INFORMATION

 

Customers :

Others, Manufacturer of Pharma

 

 

No. of Employees :

160 (Approximately)

 

 

Bankers :

·         IDBI Bank, Goa, Maharashtra, India

·         Axis Bank, Goa, Maharashtra, India

 

 

 

Banking Relations :

--

 

 

Auditors :

 

Name :

S. S. Dalvi and Company

Chartered Accountants

Address :

T-5, Souza Towers, Near Municipal Garden, Panaji, Goa – 403 001, Maharashtra, India

Tel. No.:

91-832-2223187

Qualification :

B.Com, F.C.A.

PAN No.:

AFLPD3658M

 

 

CAPITAL STRUCTURE

 

AS ON 30.09.2013

 

Authorised Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

2500000

Equity Shares

Rs.100/- each

Rs.250.000 Millions

 

 

 

 

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

251000

Equity Shares

Rs.100/- each

Rs.25.100 Millions

 

 

 

 

 


FINANCIAL DATA

[all figures are in Rupees Millions]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.03.2013

31.03.2012

31.03.2011

I.              EQUITY AND LIABILITIES

 

 

 

(1)Shareholders' Funds

 

 

 

(a) Share Capital

25.100

25.100

25.100

(b) Reserves & Surplus

(134.944)

(37.538)

(12.511)

(c) Money received against share warrants

0.000

0.000

0.000

 

 

 

 

(2) Share Application money pending allotment

0.000

0.000

0.000

Total Shareholders’ Funds (1) + (2)

(109.844)

(12.438)

12.589

 

 

 

 

(3) Non-Current Liabilities

 

 

 

(a) long-term borrowings

510.545

327.904

163.283

(b) Deferred tax liabilities (Net)

0.000

0.000

0.000

(c) Other long term liabilities

0.000

0.000

0.000

(d) long-term provisions

0.000

0.000

0.000

Total Non-current Liabilities (3)

510.545

327.904

163.283

 

 

 

 

(4) Current Liabilities

 

 

 

(a) Short term borrowings

0.000

0.000

0.000

(b) Trade payables

7.832

10.494

5.319

(c) Other current liabilities

9.031

3.318

0.174

(d) Short-term provisions

0.000

0.000

0.000

Total Current Liabilities (4)

16.863

13.812

5.493

 

 

 

 

TOTAL

417.564

329.278

181.365

 

 

 

 

II.            ASSETS

 

 

 

(1) Non-current assets

 

 

 

(a) Fixed Assets

 

 

 

(i) Tangible assets

290.441

231.940

157.824

(ii) Intangible Assets

0.000

0.000

0.000

(iii) Capital work-in-progress

46.907

27.047

0.000

(iv) Intangible assets under development

0.000

0.000

0.000

(b) Non-current Investments

0.000

0.000

0.000

(c) Deferred tax assets (net)

0.000

0.000

0.000

(d)  Long-term Loan and Advances

1.963

3.505

1.198

(e) Other Non-current assets

0.000

0.000

0.000

Total Non-Current Assets

339.311

262.492

159.022

 

 

 

 

(2) Current assets

 

 

 

(a) Current investments

0.000

0.000

0.000

(b) Inventories

18.143

46.732

7.448

(c) Trade receivables

36.365

9.631

0.000

(d) Cash and cash equivalents

14.183

6.551

1.846

(e) Short-term loans and advances

0.000

0.000

0.000

(f) Other current assets

9.562

3.872

13.049

Total Current Assets

78.253

66.786

22.343

 

 

 

 

TOTAL

417.564

329.278

181.365

 

 

PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

31.03.2013

31.03.2012

31.03.2011

 

SALES

 

 

 

 

 

Income

 

 

 

 

 

Other Income

 

 

 

 

 

TOTAL                                        

NA

4.545

NA

 

 

 

 

 

 

EXPENSES

 

 

 

 

 

TOTAL                                        

NA

47.690

NA

 

 

 

 

 

 

PROFIT/(LOSS) BEFORE TAX, DEPRECIATION AND AMORTISATION

(66.840)

(6.460)

(6.643)

 

 

 

 

 

Less

DEPRECIATION/ AMORTISATION                    

30.789

19.311

4.010

 

 

 

 

 

 

PROFIT/(LOSS) BEFORE TAX     

(97.629)

(25.771)

(10.653)

 

 

 

 

 

Less

TAX                                                                 

0.000

0.000

0.000

 

 

 

 

 

 

PROFIT/(LOSS) AFTER TAX

(97.629)

(25.771)

(10.653)

 

 

 

 

 

 

Earnings Per Share (Rs.)

388.96

NA

NA

 

 

KEY RATIOS

 

PARTICULARS

 

 

31.03.2013

31.03.2012

31.03.2011

PAT / Total Income

(%)

NA

(567.02)

NA

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

(26.34)

(8.53)

(5.87)

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

0.89

2.07

(0.85)

 

 

 

 

 

Debt Equity Ratio

(Total Debt /Networth)

 

(4.65)

(26.36)

12.97

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

4.64

4.84

4.07

 

 

FINANCIAL ANALYSIS

[all figures are in Rupees Millions]

 

DEBT EQUITY RATIO

 

Particular

31.03.2011

31.03.2012

31.03.2013

 

Rs. In Millions

Rs. In Millions

Rs. In Millions

Share Capital

25.100

25.100

25.100

Reserves & Surplus

(12.511)

(37.538)

(134.944)

Net worth

12.589

(12.438)

(109.844)

 

 

 

 

long-term borrowings

163.283

327.904

510.545

Short term borrowings

0.000

0.000

0.000

Total borrowings

163.283

1.000

510.545

Debt/Equity ratio

12.970

(0.080)

(4.648)

 

 

 

 

 

 

 

 

 

 

LOCAL AGENCY FURTHER INFORMATION

 

Sr. No.

Check List by Info Agents

Available in Report (Yes / No)

1]

Year of Establishment

Yes

2]

Locality of the firm

Yes

3]

Constitutions of the firm

Yes

4]

Premises details

No

5]

Type of Business

Yes

6]

Line of Business

Yes

7]

Promoter's background

Yes

8]

No. of employees

Yes

9]

Name of person contacted

Yes

10]

Designation of contact person

Yes

11]

Turnover of firm for last three years

Yes

12]

Profitability for last three years

Yes

13]

Reasons for variation <> 20%

-----------

14]

Estimation for coming financial year

No

15]

Capital in the business

Yes

16]

Details of sister concerns

No

17]

Major suppliers

No

18]

Major customers

No

19]

Payments terms

Yes

20]

Export / Import details (if applicable)

No

21]

Market information

----------

22]

Litigations that the firm / promoter involved in

----------

23]

Banking Details

Yes

24]

Banking facility details

No

25]

Conduct of the banking account

----------

26]

Buyer visit details

----------

27]

Financials, if provided

Yes

28]

Incorporation details, if applicable

Yes

29]

Last accounts filed at ROC

Yes

30]

Major Shareholders, if available

Yes

31]

Date of Birth of Proprietor/Partner/Director, if available

Yes

32]

PAN of Proprietor/Partner/Director, if available

No

33]

Voter ID No of Proprietor/Partner/Director, if available

No

34]

External Agency Rating, if available

No

BUSINESS OPERATION / FINANCIAL RESULTS:

 

During the period, subject has made a Net loss of Rs.97.629 Millions (Previous year Rs.25.771 Millions) after providing depreciation of Rs.30.789 Millions (Previous year Rs.19.311 Millions). The Net loss to be carried forward is Rs.97.629 Millions (Previous year Rs.25.771 Millions) comprising of depreciation loss of Rs.30.789 Millions (Previous year Rs.19.311 Millions) and business loss of Rs.66.840 Millions (Previous year Rs.6.460 Millions) including write off of input credit Rs.6.931 Millions (Previous Year NIL).

 

The directors inform that the losses of the initial years will soon be recouped within a few years once the operations start at full capacity and revenue generation increases gradually on a sustained basis.

 

 

FUTURE OUTLOOK:

 

VerGo Pharma Research Laboratories Private Limited:-

1)     Pharma Research: This division will be involved in formulation development (Pharma, Nutraceuticals, OTC, Herbals and Food Supplements), Analytical development, GMP/Clinical manufacturing and Clinical supplies, stability testing as per 1.C.H guidelines and regulatory services for the health care industry.

2)     Organics: This division will be involved in custom synthesis of impurities, metabolities, duterated compounds, reference standards, PET and nucleic acids precursors. We plan to work with leading global players to assist them in product development and custom synthesis. We plan to explore niche markets by partnering with a leading pharmaceutical company.

 

UNSECURED LOANS:

 

Particulars

31.03.2013

Rs. In Millions

31.03.2012

Rs. In Millions

Long Term Borrowings

 

 

Prasad V. Keni

0.000

114.930

V. G. Quenim

510.545

212.974

 

 

 

Total

510.545

327.904

 

 

NOTE: No Charges Exist for Company.

 

 

FIXED ASSETS:

 

·         Leasehold land

·         Factory building

·         Plant and machinery

·         Computer

·         Lab Equipments

·         Furniture and fixtures

·         Mobile handsets

·         Vehicle

·         Office Equipments

·         Books


CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                           None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                        None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                        None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 


 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.62.12

UK Pound

1

Rs.103.93

Euro

1

Rs.85.17

 

 

INFORMATION DETAILS

 

Information Gathered by :

HTL

 

 

Report Prepared by :

NKT

 


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

2

PAID-UP CAPITAL

1~10

2

OPERATING SCALE

1~10

2

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

2

--PROFITABILIRY

1~10

--

--LIQUIDITY

1~10

2

--LEVERAGE

1~10

2

--RESERVES

1~10

--

--CREDIT LINES

1~10

--

--MARGINS

-5~5

--

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

NO

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

NO

--AFFILIATION

YES/NO

NO

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

DEFAULTER

 

 

--RBI

YES/NO

NO

--EPF

YES/NO

NO

 

 

 

TOTAL

 

12

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

NB

NEW BUSINESS

 

 

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.